Two Medtronic (Minneapolis) studies, could boost the med-tech giant's diabetes control offerings in the future. The firm released results from its ASPIRE and reported that the first patients for its Overnight Closed Loop Platform study have already been enrolled. News on the studies was revealed at the American Diabetes Association (ADA; Alexandria, Virginia) 73rd Scientific Sessions.